---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-024522"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2026-07-27T20:33:24+00:00"
generated_at: "2026-07-27T20:34:17.315386+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q2 net loss $4.4M ($0.97/share); advancing GEO-MVA pivotal study planned Q4 2026

## Summary
- Net loss for Q2 2026 was $4.4M ($0.97 per share) vs $5.4M ($8.74 per share) in Q2 2025.
- No revenue in Q2 2026 after BARDA contract termination; Q2 2025 had $852K government contract revenue.
- Cash $3.1M at June 30, 2026, unchanged from Dec 31, 2025.
- Discontinued GEO-CM04S1 COVID-19 vaccine development due to market contraction; no safety concerns.
- Planning to initiate pivotal GEO-MVA immunobridging study in Q4 2026 under EMA expedited pathway.

## SEC filing metadata
- accession: 0001437749-26-024522
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2026-07-27T20:33:24+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/0001437749-26-024522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/govx20260727_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-024522
- JSON: https://secwatch.observer/filing/0001437749-26-024522.json
- Plain text: https://secwatch.observer/filing/0001437749-26-024522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.